EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).
TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
申请人:Shanghai Jemincare Pharmaceuticals Co., Ltd.
公开号:EP3998263A1
公开(公告)日:2022-05-18
A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.